Built for PSX investors
Your market watch, portfolio and news desk in one app.
Follow live PSX prices, track holdings, read business news, and keep your watchlist close before the market moves.
Built for PSX investors
Follow live PSX prices, track holdings, read business news, and keep your watchlist close before the market moves.
Abbott Laboratories (Pakistan) Limited reported unaudited results for the six months ended June 30, 2026. Sales, gross profit, profit for the period and EPS increased year over year. Cash and cash equivalents were lower than at December 31, 2025.
| Metric | PreviousSix months ended June 30, 2025 | CurrentSix months ended June 30, 2026 | Change |
|---|---|---|---|
| Sales - net | 36,407,789 | 38,026,551 | +4.4% |
| Gross Profit | 12,614,900 | 14,450,106 | +14.5% |
| Profit for the period | 3,543,172 | 4,140,231 | +16.9% |
| Earnings per share - basic and diluted | 36.19 | 42.29 | +16.9% |
| Finance costs | (37,704) | (35,643) | -5.5% |
| Cash and cash equivalents | 13,337,551 | 9,436,049 | -29.3% |
Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.
Get Investify
The information on Investify is for informational purposes only and is not financial, investment, legal or tax advice. Market data, announcements, news, highlights, Buy/Sell/Neutral labels and other values may be sourced from or relate to Recube Technologies LLP, third-party providers and automated systems; none of these parties guarantees the timeliness, accuracy, completeness, correct sequencing, reliability or availability of such information. Nothing on the website or app is an offer, solicitation, recommendation or advice to buy, sell, hold or enter into any transaction. Investing involves risk, and users are responsible for verifying original sources and consulting qualified advisers before making investment decisions.
© 2026 Investify. All rights reserved.
